GENTICEL
Genticel is a French clinical stage biotechnology company founded by Benedikt Timmerman in 2001 and focused on the development of innovative immunotherapies designed to treat virus infections and virus-induced diseases. Genticel aims to become a leader in immunotherapy in multiple indications, starting with HPV and HPV induced diseases such as cervical cancer.
GENTICEL
Social Links:
Industry:
Biotechnology Medical Device Therapeutics
Founded:
2001-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.genticel.com
Total Employee:
11+
Status:
Closed
Contact:
+33 5 61 28 70 60
Total Funding:
41.38 M USD
Technology used in webpage:
Domain Not Resolving Adobe Dreamweaver
Current Employees Featured
Founder
Investors List
Andera Partners
Andera Partners investment in Series D - Genticel
InnoBio Fund
InnoBio Fund investment in Series D - Genticel
Idinvest Partners
Idinvest Partners investment in Series D - Genticel
Wellington Partners
Wellington Partners investment in Series D - Genticel
Amundi Private Equity Funds
Amundi Private Equity Funds investment in Series D - Genticel
Andera Partners
Andera Partners investment in Series C - Genticel
InnoBio Fund
InnoBio Fund investment in Series C - Genticel
Amundi Private Equity Funds
Amundi Private Equity Funds investment in Series C - Genticel
Idinvest Partners
Idinvest Partners investment in Series C - Genticel
More informations about "Genticel"
Genticel | Labège, Midi-Pyrénées, France Startup
Genticel is a clinical stage biotechnology company focused on developing multivalent vaccines against Human Papillomavirus (HPV) infections which are the known cause for several …See details»
Genticel Company Profile - Office Locations, Competitors ... - Craft
Genticel Société Anonyme, a clinical stage biotechnology company, develops immunotherapies to prevent cancers caused by the human papillomavirus (HPV). The company develops GTL001, …See details»
Genticel S.A. - Labège, France - bionity.com
Genticel aims to become a leader in immunotherapy in multiple indications, starting with HPV and HPV induced diseases such as cervical cancer. To achieve this goal, we have developed a …See details»
Genticel 2025 Company Profile: Valuation, Investors, …
Genticel General Information Description. Genkyotex SA is a biopharmaceutical company. It is engaged in the business of research, study, manufacturing and …See details»
Genticel - Headquarter Location, Corporate Office Address and …
Genticel is Biotechnology in France that focus on health products business. Founded in 2001. They cover business area such as Genkyotex SA, research, study, manufacturing, distribution, …See details»
Genticel - Products, Competitors, Financials, Employees, …
Genticel, formerly BT Pharma, develops therapeutic solutions for women already infected by the human papillomavirus (HPV) before high grade lesions or cervical cancer occur. Use the CB …See details»
Genticel SA:Company Profile & Technical Research,Competitor …
Genticel SA is a company that provides Immunotherapy, Medical equipment, Pharmacy and Therapeutics and more. Genticel SA is headquartered in France . Genticel SA was founded in …See details»
Genticel Overview | SignalHire Company Profile
Genticel is a private company that has been in the industry for 23 years. The company currently specializes in the Biotechnology area. The position of the Chairman & CEO is occupied by …See details»
Genticel, the biotech fighting HPV
Jun 10, 2016 Genticel is a clinical biotech developing a cervical cancer immunotherapy against the Human papillomavirus (HPV), which causes around 70% of cases of cervical cancer. With its two leading molecules, Genticel is …See details»
Genticel SA Company Profile, Financial and Strategic SWOT …
DigitGaps report on Genticel SA delivers a detailed in-depth and comprehensive insights of the company, its history, corporate strategy, its businesses and structures, and company …See details»
Genticel: Contact Details and Business Profile - RocketReach
Genticel is a French clinical stage biotechnology company founded by Benedikt Timmerman in 2001 and focused on the development of innovative immunotherapies designed to treat virus …See details»
[ 2025] Genticel Mckinsey 7S Analysis / Framework - EMBA Pro
Mickinsey 7S framework is used to analyze Genticel – competitive strategy, organization structure, human resources framework, culture, mission vision, and value statements, and …See details»
Genticel Definition - Law Insider
Define Genticel. or the “Company” refers to Genkyotex (formerly Genticel), a limited company (société anonyme) with shares admitted to trading on the Euronext Paris and Euronext …See details»
Genticel - Funding, Financials, Valuation & Investors - Crunchbase
Experience the new Crunchbase, powered by AI . Organization. GenticelSee details»
Genticel : Genticel becomes Genkyotex | MarketScreener
Feb 28, 2017 The new group's organization chart. From today, the Company's corporate name and trading name (“Genticel” prior to the General Meeting) is “Genkyotex”. To avoid the risk of …See details»
Genticel (France) Organizational Resilience Analysis - EMBA Pro
Organization Resilience Introduction . The world is going through two major crises at the moment – Covid 19 health crisis and the on-going US China trade war that can determine the future of …See details»
Genticel Headquarters and Office Locations - Craft.co
Genticel Headquarters and Office Locations. Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit. Button CTA. Genticel is headquartered in Labège, 516 Rue Pierre …See details»
Genticel - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Genticel . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. Genticel has 1 …See details»
Genticel Leadership with Empathy & Compassion | EMBA Pro
Leaders at Genticel can use compassion along with empathy to lead the employees in the organization. The key differences using both compassion and empathy, rather than just …See details»
COVID-19 - Global Situation - World Health Organization (WHO)
May 28, 2025 Since mid-February 2025, according to data available from sentinel sites, global SARS-CoV-2 activity has been increasing, with the test positivity rate reaching 11%, levels …See details»